POC(Point-of-Care) 검사 시장(2024-2031년)

Key Takeaways: Point-of-Care Testing Market

• The Point-of-Care Testing Market is undergoing rapid transformation as decentralized diagnostics, AI-enabled clinical intelligence, and connected healthcare ecosystems improve patient care and accelerate clinical decision-making.
• Rising demand for rapid molecular diagnostics, home-based testing, and CLIA-waived diagnostic solutions is expanding the point of care diagnostics market across hospitals, ambulatory centers, retail clinics, and remote healthcare settings.
• Molecular and immunochemistry testing remain the dominant technology segments, supported by higher diagnostic accuracy, multiplex testing capabilities, and shorter sample-to-result times.
• Artificial intelligence, cloud connectivity, telehealth integration, and digital pathology are enabling smarter diagnostic workflows and personalized healthcare delivery.
• Regulatory compliance, interoperability, workforce training, and clinical validation remain key challenges, while precision medicine and decentralized healthcare continue to create long-term opportunities for the Point of Care Diagnostics Market.

Report Summary: Point-of-Care Testing Market

The Point-of-Care Testing Market is rapidly evolving from conventional rapid diagnostic testing into an intelligent, connected healthcare ecosystem that enables decentralized clinical decision-making. Growing demand for faster diagnosis, early disease detection, and personalized treatment is accelerating the adoption of advanced testing technologies across hospitals, physician offices, ambulatory care centers, retail clinics, pharmacies, home healthcare settings, and remote medical facilities. The expansion of molecular diagnostics and highly sensitive immunochemistry platforms continues to improve diagnostic accuracy while reducing turnaround time for clinicians and patients.

The point of care diagnostics market is benefiting from technological advancements such as artificial intelligence, cloud-based connectivity, digital pathology, multiplex testing, and real-time clinical decision support systems. The increasing availability of CLIA-waived diagnostic devices has further simplified testing procedures, enabling healthcare providers to perform high-quality diagnostic testing outside centralized laboratories. Home-based testing and self-monitoring solutions are also becoming increasingly important, particularly for chronic disease management and infectious disease surveillance.

Continuous innovation in molecular diagnostics, syndromic testing, precision medicine, and connected healthcare platforms is creating new growth opportunities for the Point of Care Diagnostics Market. While regulatory complexity, interoperability challenges, and workforce limitations remain key obstacles, ongoing investments in AI-powered diagnostics, decentralized laboratory infrastructure, and digital healthcare integration are expected to support sustained market expansion through 2031.

Market Overview & Trends: Point-of-Care Testing Market

The Point-of-Care Testing Market is experiencing significant growth as healthcare providers increasingly adopt decentralized diagnostic solutions that enable faster clinical decisions and improved patient outcomes. The shift away from centralized laboratory testing toward near-patient diagnostics is transforming healthcare delivery by providing timely, accurate, and accessible testing across hospitals, outpatient facilities, retail clinics, pharmacies, emergency departments, community health centers, and home care environments. This evolution has positioned the point of care diagnostics market as one of the fastest-growing segments within the global diagnostics industry.

One of the most important trends shaping the Point-of-Care Testing Market is the rapid adoption of molecular diagnostics. Unlike traditional rapid tests, molecular point-of-care systems deliver laboratory-quality accuracy while significantly reducing turnaround times. Healthcare providers are increasingly utilizing these technologies for infectious disease detection, respiratory illnesses, sexually transmitted infections, antimicrobial resistance monitoring, and oncology applications. Simultaneously, advances in immunochemistry continue to enhance biomarker detection, supporting earlier diagnosis and more personalized treatment decisions.

Artificial intelligence is becoming a major differentiator in the Point of Care Diagnostics Market. AI-powered diagnostic algorithms, digital pathology, predictive analytics, and automated result interpretation improve clinical accuracy while reducing human error. Integration with cloud platforms, electronic health records (EHRs), telehealth systems, and clinical decision-support software enables seamless sharing of diagnostic information across healthcare networks.

Another defining trend is the expansion of CLIA-waived testing, allowing healthcare professionals to perform complex diagnostic procedures without traditional laboratory infrastructure. This capability has increased testing accessibility in physician offices, pharmacies, urgent care centers, and rural healthcare facilities. The growing popularity of home-based testing and self-testing solutions is also expanding the addressable market, particularly for chronic disease monitoring, diabetes management, cardiovascular health, and infectious disease screening.

Precision medicine continues to reshape the point of care diagnostics market, with companion diagnostics, multiplex testing, and syndromic panels supporting individualized treatment strategies. Simultaneously, continuous glucose monitoring (CGM), wearable biosensors, and connected diagnostic devices are enabling real-time health monitoring and personalized patient management.

Despite strong growth prospects, the Point-of-Care Testing Market must address regulatory compliance, interoperability challenges, clinical validation requirements, reimbursement complexities, and workforce training needs. Nevertheless, continued technological innovation, increasing healthcare digitization, expanding home healthcare adoption, and growing demand for decentralized diagnostics are expected to sustain long-term growth, positioning the Point of Care Diagnostics Market as a critical component of next-generation healthcare delivery.

Scope of Analysis: Point-of-Care Testing Market

The Point-of-Care Testing Market study provides a comprehensive assessment of the global diagnostic testing landscape, focusing on the rapid transition from centralized laboratory testing to decentralized, near-patient diagnostic solutions. The report evaluates market performance across major healthcare settings, including hospitals, outpatient clinics, physician offices, pharmacies, retail clinics, home healthcare, and community-based care. The study covers the period from 2025 to 2031, with 2025 as the base year and forecasts extending from 2026 to 2031, using US dollars as the monetary unit.

The research analyzes both molecular and immunochemistry-based testing technologies, highlighting their applications in infectious disease diagnosis, chronic disease management, oncology, cardiovascular disorders, and personalized medicine. It also examines the adoption of CLIA-waived testing, AI-enabled diagnostics, digital pathology, multiplex testing, and connected healthcare platforms that are transforming the point of care diagnostics market.

Geographically, the study evaluates market trends across North America, Europe, Asia-Pacific, and emerging regions including the Middle East, Africa, and Latin America. It further assesses regulatory frameworks, reimbursement trends, technology adoption, clinical workflows, competitive dynamics, and investment opportunities. This broad analytical framework enables stakeholders to understand current market conditions, emerging innovations, and long-term growth prospects within the Point of Care Diagnostics Market.

Market Segmentation Analysis: Point-of-Care Testing Market

The Point-of-Care Testing Market is segmented by technology, testing complexity, application, care setting, and geographic region to provide a comprehensive understanding of industry dynamics and future growth opportunities. These segments highlight how evolving healthcare needs and technological advancements are reshaping the global point of care diagnostics market.

By technology, the market is primarily divided into molecular diagnostics and immunochemistry diagnostics. Molecular point-of-care testing is experiencing rapid adoption due to its laboratory-grade accuracy, multiplex testing capabilities, and ability to detect infectious diseases quickly at decentralized locations. Immunochemistry testing remains an essential segment for measuring biomarkers, hormones, proteins, cardiac markers, and other analytes that support routine diagnosis and disease monitoring.

Based on testing complexity, the market includes point-of-need, CLIA-waived, and moderately complex diagnostic systems. CLIA-waived testing continues to gain popularity because it allows healthcare professionals to perform reliable diagnostic procedures without requiring sophisticated laboratory infrastructure, thereby expanding testing accessibility across diverse healthcare environments.

Application-based segmentation covers infectious diseases, diabetes, cardiovascular diseases, oncology, respiratory disorders, women's health, chronic disease monitoring, and other specialized clinical areas. Infectious disease diagnostics continue to dominate market demand, while chronic disease management and precision medicine applications are creating new opportunities for long-term market expansion.

From an end-user perspective, the Point of Care Diagnostics Market serves hospitals, physician offices, outpatient clinics, ambulatory surgical centers, pharmacies, retail health clinics, home healthcare providers, mobile clinics, correctional facilities, airports, and digital healthcare platforms. Growing demand for home-based diagnostics and remote patient monitoring is significantly expanding the addressable market.

Regionally, North America currently represents the largest share of the point of care diagnostics market, supported by advanced healthcare infrastructure, favorable reimbursement, and rapid technology adoption. Europe continues to invest heavily in decentralized healthcare, while Asia-Pacific is emerging as the fastest-growing region due to expanding healthcare access, rising disease prevalence, increasing government investments, and rapid adoption of digital healthcare technologies. Emerging markets across Latin America, the Middle East, and Africa are also witnessing increasing adoption as healthcare systems prioritize affordable, rapid, and decentralized diagnostic solutions.

Growth Drivers: Point-of-Care Testing Market

The Point-of-Care Testing Market is being driven by the growing demand for decentralized healthcare, rapid diagnostics, and connected clinical ecosystems that enable faster medical decision-making. One of the strongest growth catalysts is the increasing adoption of multi-disease molecular POCT platforms capable of detecting multiple infectious diseases through a single test. These systems provide laboratory-quality accuracy while delivering results within minutes, making them ideal for hospitals, ambulatory care centers, physician offices, and community healthcare settings.

The expanding availability of CLIA-waived diagnostic tests is another significant driver for the point of care diagnostics market. These tests simplify diagnostic workflows by allowing healthcare providers to perform high-quality testing outside traditional laboratories, improving accessibility in remote and underserved regions. Home-based testing and self-monitoring solutions are also gaining momentum, driven by consumer preference for convenient healthcare and continuous chronic disease management.

Artificial intelligence (AI), digital pathology, and cloud-based connectivity are transforming the Point of Care Diagnostics Market by enabling automated result interpretation, predictive analytics, and seamless integration with electronic health records and telehealth platforms. These technologies improve diagnostic accuracy, reduce clinician workload, and support personalized treatment decisions.

Additionally, the growing prevalence of chronic diseases, increasing demand for precision medicine, and expanding investments in connected healthcare infrastructure continue to accelerate market growth. The convergence of molecular diagnostics, AI-enabled clinical intelligence, and real-time data sharing is expected to position the Point-of-Care Testing Market as a cornerstone of future healthcare delivery.

Growth Restraints: Point-of-Care Testing Market

Despite its strong growth potential, the Point-of-Care Testing Market faces several operational and regulatory challenges. One of the most significant restraints is the complexity of regulatory approvals and implementation requirements. Molecular and decentralized diagnostic systems must comply with rigorous quality standards, clinical validation protocols, and regulatory frameworks, increasing development costs and extending commercialization timelines.

Data integration and interoperability also present major challenges for the point of care diagnostics market. As healthcare providers increasingly adopt connected diagnostic devices, seamless integration with hospital information systems, laboratory information management systems, and electronic health records remains difficult. Poor interoperability can disrupt clinical workflows and reduce the effectiveness of decentralized diagnostics.

Operational challenges further restrain market growth. Many healthcare facilities continue to experience shortages of trained personnel capable of operating advanced POCT devices, maintaining quality assurance, and interpreting complex diagnostic results. Standardized training programs remain essential for ensuring reliable clinical performance.

Another important limitation is the need for stronger clinical validation and real-world evidence, particularly for emerging molecular diagnostic technologies. Healthcare providers and regulatory agencies require comprehensive evidence demonstrating clinical utility, diagnostic accuracy, and improved patient outcomes before widespread adoption. Addressing these challenges will be essential for sustaining long-term growth in the Point of Care Diagnostics Market.

Competitive Landscape: Point-of-Care Testing Market

The Point-of-Care Testing Market is highly competitive, with global diagnostics companies continuously investing in molecular diagnostics, immunochemistry platforms, artificial intelligence, digital health integration, and decentralized testing technologies. Competition within the point of care diagnostics market is based on diagnostic accuracy, testing speed, multiplex capabilities, connectivity, ease of use, regulatory approvals, and integration with broader healthcare ecosystems.

North America remains the largest and most technologically advanced regional market, led by companies such as Abbott, Roche Diagnostics, QuidelOrtho, Danaher, Siemens Healthineers, Qiagen, bioMerieux, Becton Dickinson (BD), Bio-Rad Laboratories, and Hologic. These organizations continue expanding their product portfolios through innovation, strategic partnerships, and acquisitions while strengthening their presence across hospitals, physician offices, pharmacies, and home healthcare.

In Europe, major participants include Roche Diagnostics, Siemens Healthineers, Sysmex, Qiagen, bioMerieux, Philips, EKF Diagnostics, Biosynex, Randox Laboratories, and Trinity Biotech. These companies emphasize advanced molecular diagnostics, automation, digital pathology, and AI-enabled clinical decision support to enhance healthcare efficiency.

The Asia-Pacific region is witnessing rapid expansion with companies such as PHC Holdings, ARKRAY, Sansure Biotech, SD Biosensor, Getein Biotech, Sinocare, Tellgen Corporation, and BioHermes investing heavily in affordable diagnostic technologies and localized manufacturing capabilities. Meanwhile, emerging markets across the Middle East, Africa, and Latin America feature growing participation from regional diagnostic manufacturers and distributors focused on expanding healthcare accessibility.

As healthcare increasingly shifts toward decentralized, connected, and personalized care, the Point of Care Diagnostics Market is expected to experience continued innovation driven by AI integration, home-based diagnostics, multiplex molecular testing, remote patient monitoring, and digital healthcare ecosystems.

Frequently Asked Questions (FAQs) – Point-of-Care Testing Market

• 1. What is the Point-of-Care Testing Market?
  • The Point-of-Care Testing Market includes diagnostic technologies that enable rapid medical testing at or near the patient, eliminating the need for centralized laboratory processing and enabling faster clinical decisions.
• 2. What is driving growth in the point of care diagnostics market?
  • Growth is driven by decentralized healthcare, molecular diagnostics, CLIA-waived testing, AI-enabled diagnostic platforms, home-based testing, chronic disease management, and increasing demand for rapid clinical decision-making.
• 3. Which technologies dominate the Point of Care Diagnostics Market?
  • Molecular diagnostics and immunochemistry testing are the leading technologies, supported by multiplex testing, AI-powered analytics, digital pathology, and cloud-connected diagnostic platforms.
• 4. What are CLIA-waived tests?
  • CLIA-waived tests are simple, low-risk diagnostic procedures approved for use outside traditional laboratories, allowing healthcare professionals to perform rapid testing in clinics, pharmacies, and physician offices.
• 5. Which healthcare settings use point-of-care testing?
  • Point-of-care testing is widely used in hospitals, physician offices, ambulatory care centers, retail clinics, pharmacies, home healthcare, emergency departments, and remote healthcare facilities.
• 6. What challenges affect the Point-of-Care Testing Market?
  • Major challenges include regulatory complexity, interoperability issues, workforce training requirements, reimbursement limitations, and the need for stronger clinical validation of emerging technologies.
• 7. Which companies are leading the Point of Care Diagnostics Market?
  • Leading companies include Abbott, Roche Diagnostics, Siemens Healthineers, QuidelOrtho, Danaher, Qiagen, bioMerieux, BD, Hologic, Sysmex, and PHC Holdings, among others.
• 8. How is artificial intelligence transforming point-of-care diagnostics?
  • AI improves diagnostic accuracy through automated image analysis, predictive analytics, clinical decision support, workflow optimization, and integration with digital healthcare systems.
• 9. Which region leads the global Point-of-Care Testing Market?
  • North America currently leads the market due to advanced healthcare infrastructure, high adoption of molecular diagnostics, favorable reimbursement policies, and continuous technological innovation.
• 10. What is the future outlook for the Point-of-Care Testing Market?
  • The market is expected to grow steadily through 2031 as molecular diagnostics, AI-enabled clinical intelligence, connected healthcare ecosystems, home-based testing, and precision medicine become increasingly integrated into routine healthcare delivery.

Scope and Segmentation

• Scope of Analysis
• Segmentation
• Key Market Highlights

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8TM
• The Impact of the Top 3 Strategic Imperatives on the POCT Industry

Growth Opportunity Analysis

• Growth Drivers
• Growth Driver Analysis
• Growth Restraints
• Growth Restraint Analysis
• POCT's Structural Shifts
• Molecular and Immunochemistry POCT Converging Toward High-Sensitivity, Multiplexed Precision Testing
• Competitor Environment, By Region
• Continuous Glucose Monitoring (CGM) Emerging as a High-Growth POCT Segment in Decentralized Diabetes Management
• Ecosystem Integration and Portfolio Expansion Strengthen Competitive Differentiation in POCT
• Breakthrough Innovations in the POCT Industry
• Global POCT Competitive Landscape
• Clinical Decision Support and Connected POCT Ecosystems
• Decentralized POCT Clinical Continuum
• Home Testing: Transforming POCT into Consumer-Centric Diagnostics
• Trends Strengthening POCT
• Regulatory Landscape
• Growth Opportunity Matrix: Predictions for 2026
• Companies to Action (C2A)
• Advanced Biomarker Detection, Monitoring, and Precision POCT

Growth Opportunity Universe

• Growth Opportunity 1: Decentralized Precision Oncology Through Near-Patient Molecular Decisioning
• Growth Opportunity 2: Isothermal Amplification and Ultra-Rapid Molecular POCT Redefining Time-to-Clinical Action
• Growth Opportunity 3: Real-Time Clinical Intelligence Networks Driven by Connected POCT Ecosystems

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Legal Disclaimer